Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adductor canal block with ropivacaine for recovery after arthroscopic knee surgery
ACTRN12616000935437Phase 4Completed
- Sponsor
- Yusheng Pharmaceutical
- Start
- Sep 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ropivacaine in postoperative pain (2 arms), sponsored by Yusheng Pharmaceutical. Primary endpoint: Quality of recovery. Started Sep 2016; status: completed.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ACTRN12616000935437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000935437.